Skip to content
OpenCapital
Get started

Novavax NVAX Accounts Receivable, after Allowance for Credit Loss

Accounts Receivable, after Allowance for Credit Loss at other companies

Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNet.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's accounts receivable, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's accounts receivable, after allowance for credit loss?
Novavax (NVAX) reported accounts receivable, after allowance for credit loss of $23.31M in Q1 2026.
How has Novavax's accounts receivable, after allowance for credit loss changed year-over-year?
Novavax's accounts receivable, after allowance for credit loss decreased by 47.6% year-over-year, from $44.51M to $23.31M.
What is the long-term trend for Novavax's accounts receivable, after allowance for credit loss?
Over 4 years (2021 to 2025), Novavax's accounts receivable, after allowance for credit loss has grown at a -30.5% compound annual growth rate (CAGR), from $454.99M to $106.45M.